Latest Us Growth News

Cobram Estate Olives has secured $175 million through an institutional placement to accelerate its expansion in the US, aiming to increase its Californian olive groves to 3,600 hectares and boost olive oil production significantly by 2027.

QuickFee Limited has divested its US Pay Now payments business for US$26.35 million while keeping its US Finance operations and loan book, withdrawing FY26 earnings guidance amid ongoing tax and transaction cost assessments.

Althea Group Holdings reports a significant reduction in losses for FY25, driven by asset sales and strategic refocus on North American THC beverages. The company completed a $4 million capital raise and navigated leadership changes amid subsidiary liquidations.

Wiseway Group has delivered its strongest financial performance since listing, powered by a booming US division and a sharp focus on eCommerce imports across key markets.

Airtasker Limited reported a robust FY25 with marketplaces revenue growth accelerating to 18.3%, positive free cash flow, and significant expansion in the UK and US markets. Strategic media partnerships and brand investments underpin this momentum as the company sets sights on further growth in FY26.

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.

Nova Eye Medical has delivered solid FY25 results, meeting sales guidance outside China and achieving six consecutive halves of growth in the US market. The company also improved gross margins and reduced cash burn, setting an optimistic tone for FY26 with breakeven EBITDA guidance.

Nova Eye Medical has reported a record A$29.3 million in FY25 revenue, driven by sustained US growth and operational improvements, setting the stage for breakeven EBITDA in the first half of FY26.

Compumedics has reported record-breaking sales orders and revenues for FY25, driven by strong US market growth and SaaS adoption, setting the stage for an ambitious FY26 expansion.

Genetic Signatures Limited reported a 63% revenue surge to $15.9 million in FY25, driven by strong Australian sales and progress in EMEA, while navigating a $20.1 million net loss and a strategic pivot towards partnerships for automated diagnostics.

Zip Co Limited’s FY25 results reveal a powerful US market expansion driving a 147% rise in cash earnings and a strategic Nasdaq dual listing consideration.

Zip Co has delivered a standout FY25 with cash earnings soaring 147%, driven by rapid US market expansion. The company is now considering a Nasdaq dual listing to fuel further growth.